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Abstract Squamous cell carcinoma of the lung accounts
for 20–30 % of non-small cell lung cancers (NSCLC).
Despite the differences in disease characteristics between
squamous and non-squamous NSCLC, both have histori-
cally been treated similarly in the clinic. Recently approved
drugs have revealed differences in activity and safety
profiles across histologic subtypes and have applicability in
treating non-squamous, but not typically squamous,
NSCLC. Exploration of immune checkpoints—co-inhibi-
tory molecules used to regulate immune responses—has
resulted in novel immunotherapies designed to interrupt
signaling through the cytotoxic T lymphocyte-associated
antigen-4 or programmed cell death protein-1 pathways on
lymphocytes. Modulation of these pathways can lead to
restored antitumor immune responses, and preliminary
evidence shows that agents targeting these pathways have
activity in lung cancer, including squamous NSCLC.
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Background
The first-line treatment for advanced non-small cell lung
cancer (NSCLC) depends on the tumor histology and the
presence of epidermal growth factor receptor (EGFR)
mutation or anaplastic lymphoma kinase (ALK) rear-
rangements. For NSCLC with mutated EGFR or positive
for ALK, treatment with an EGFR tyrosine kinase inhibitor
(e.g., erlotinib or afatinib) or ALK inhibitor (e.g., crizoti-
nib), respectively, is recommended. These molecular
abnormalities are more common in patients who have
adenocarcinoma. For patients with non-squamous NSCLC
without an actionable molecular abnormality, the standard
therapy remains chemotherapy with or without bev-
acizumab. Patients with squamous histology have experi-
enced a prohibitive rate of severe pulmonary hemorrhage
when treated with bevacizumab, and bevacizumab is,
therefore, contraindicated in patients with squamous his-
tology tumors [1, 2]. The activity of pemetrexed is limited
to non-squamous histology [3]. Therefore, additional
options to combat squamous NSCLC are needed, and based
on the preliminary findings to date, there is hope that
immunotherapy will prove to be a novel therapeutic
approach that is not limited by histologic subtype.
Newer data are providing a better understanding of how
lung cancer can avoid immune detection or elimination and
persist as clinical disease. As a result, immunotherapeutic
approaches for the treatment of lung cancer treatment are
rapidly evolving. These include novel agents, known as
immune checkpoint inhibitors, which target mechanisms
used by tumors for immune evasion. This immunotherapy
approach differs from antigen-specific vaccines in that it
targets the entire immune system. Immune checkpoints are
co-inhibitory molecules that serve to balance or attenuate
co-stimulatory pathways that lead to immune activation. In
normal tissues, immune checkpoint pathways prevent
overactivation of the immune system to protect self-tissues.
In cancer, however, tumors can utilize immune checkpoint
pathways to evade immune system recognition by
T. E. Stinchcombe (&)
Multi-disciplinary Thoracic Oncology Program, University of
North Carolina UNC Chapel Hill, Physicians Office Bldg. CB#




Med Oncol (2014) 31:960
DOI 10.1007/s12032-014-0960-1
expressing co-inhibitory molecules or their ligands [4–6].
Several of these co-inhibitory molecules [e.g., programmed
cell death protein-1 (PD-1), its ligands PD-L1 and PD-L2,
and cytotoxic T lymphocyte-associated antigen-4 (CTLA-
4)] have been linked to tumoral immune escape. Immune
checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1
have shown promising clinical activity in patients with
melanoma and, more recently, clinical activity in NSCLC
across histologic subtypes [7–15].
This article will review differences between the histo-
logic and immunologic characteristics of squamous versus
non-squamous NSCLC, provide a brief overview of the
biology of immune checkpoint inhibitors, and discuss the
potential future role of antibody-mediated immune modu-
lation in squamous NSCLC based on clinical experience to
date.
Differences in histologic and immunologic
characteristics between squamous and non-squamous
NSCLC
Squamous and non-squamous NSCLC are recognized as
distinct diseases, differing in terms of histologic and
immunologic characteristics. Compared with non-squa-
mous NSCLC, squamous NSCLC is associated with a
higher likelihood of smoking, central tumor growth, and
cavitation [16]. These differences between squamous and
non-squamous NSCLC may influence the response to
therapeutic agents, as exemplified by the differential pro-
files of targeted agents. Therefore, clinical trials are now
starting to enroll patients by histologic type.
Histologic characteristics
Well-differentiated squamous cell NSCLC is characterized
by keratinization, intercellular bridges, and pearl formation
[16, 17]. Tumor cells tend to be large with abundant dense
cytoplasm, irregular hyperchromatic nuclei, and small
nucleoli. For tumors without clearly differentiated mor-
phology, analysis of p63 and thyroid transcription factor-1
(TTF-1) can be used to determine lineage [17]. Squamous
cell carcinoma has a consistent histologic marker profile,
namely diffuse expression of p63/CK5/6/34bE-12 and non-
expression of TTF-1 [18]. In contrast, adenocarcinoma
shows significant expression heterogeneity for all ‘squa-
mous markers’; only diffuse TTF-1 expression is specific
for adenocarcinoma. During attempts to refine histologic
classification based on p63 expression, investigators found
that TAp63, a p53-like tumor suppressor, was detected in
100 % of squamous cell carcinomas and in 31 % of ade-
nocarcinomas. In contrast, expression of DNp63, an
oncogene, was detected in 100 % of squamous cell carci-
nomas, but in only 3 % of adenocarcinomas [19].
Immunologic characteristics
Many tumor antigens of interest in lung cancer, including
melanoma-associated antigens A3 and A4 and NY-ESO-1,
have more frequent expression in squamous tumors than in
non-squamous tumors [20–23]. Furthermore, immunohis-
tochemical analyses have shown that squamous NSCLC
tumors have more extensive infiltration of CD8 ? effector
cells than do non-squamous tumors. However, the
increased numbers of tumor-infiltrating CD8 ? T cells did
not correlate with a survival advantage, suggesting an
impotent immune response, possibly due to an immuno-
suppressive tumor environment [24–26]. Genomic analysis
of squamous cell carcinomas found that many samples
exhibited inactivating mutations in the human leukocyte
antigen-A class I major histocompatibility gene, which
could lead to loss-of-function and reduced expression of
tumor antigens, a possible immune-evading strategy [27].
Biology of immune checkpoint inhibitors
CTLA-4 blockade
The CTLA-4 receptor is expressed on T cells, and its
interaction with ligands B7-1 (CD80) and B7-2 (CD86) is
thought to attenuate T cell activation early in the activation
process when the T cells are in the draining lymph nodes
[28, 29]. CTLA-4 competes with the co-stimulatory
receptor CD28 for B7 binding, preventing sustained T cell
activation [30–32]. Blockade of CTLA-4 using monoclonal
antibodies induces antitumor activity in murine cancer
models, via both direct enhancement of T effector cells and
concomitant inhibition of regulatory T cells [33–35].
PD-1/PD-L1 blockade
Binding of the PD-1 receptor on T cells to its ligands, the
most well characterized of which are PD-L1 and PD-L2, is
another mechanism by which the immune system down-
regulates T cell activity; this pathway is thought to act later
in the antitumor process, in the tumor microenvironment
[36–38]. As evidence for this pathway’s role in immune
evasion, PD-1 expression has been found on tumor-infil-
trating T cells [39, 40], as has expression of PD-1 ligands
on various tumor types, including squamous NSCLC [36,
41, 42]. In addition to T cells, B cells and natural killer
cells can also express PD-1, which may reduce their anti-
tumor activity [43].
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PD-1:PD-L2 binding has higher affinity and is slightly
different compared with PD-1:PD-L1 binding, although it
is unclear whether these differences translate to different
antitumor effects [44]. There is also evidence that PD-L1
may interact with CD80 (B7-1) expressed on T cells to
suppress T cell activity [45, 46]. In preclinical models,
antibody blockade of PD-1 or its ligands induces antitumor
activity in murine cancer models through enhancement of
T cell activity, which served as the basis for clinical
development of PD-1 pathway-targeting agents [36, 47,
48].
Preliminary clinical experience with immune
checkpoint inhibitors in squamous NSCLC
Ipilimumab
Ipilimumab is an anti-CTLA-4 monoclonal antibody that
binds to the CTLA-4 receptor, which restores CD28 sig-
naling and allows immune activation to persist. In a ran-
domized phase II study in previously untreated patients
with NSCLC, the combination of ipilimumab with paclit-
axel and carboplatin as a phased regimen (i.e., 2-dose
chemotherapy lead-in) significantly improved immune-
related progression-free survival (irPFS) and modified
World Health Organization-PFS compared with chemo-
therapy alone (Table 1) [9]. The PFS advantage was not
observed when ipilimumab was administered concurrently
with chemotherapy (i.e., no chemotherapy lead-in); it is not
clear whether these observations can be applied to other
immune checkpoint inhibitors. Overall survival (OS) was
longer in the phased ipilimumab treatment group, but the
difference was not statistically significant. Subgroup ana-
lysis by histology indicated that the phased ipilimumab/
chemotherapy regimen showed activity in both squamous
and non-squamous NSCLC (Fig. 1). An ongoing phase III
study (NCT01285609) is further evaluating the clinical
efficacy of ipilimumab in combination with chemotherapy
in patients with squamous NSCLC (Table 2).
MK-3475
MK-3475 is a humanized antibody against PD-1. MK-3475
and nivolumab (discussed below) both target PD-1 and are
designed to inhibit PD-1 from binding its ligands, PD-L1
and PD-L2. In a phase I study, MK-3475 was administered
at 10 mg/kg every 3 weeks to NSCLC patients previously
treated with two systemic regimens [14]. Interim data on
38 patients showed an objective response rate (ORR) by
Response Evaluation Criteria in Solid Tumors (RECIST)
v1.1 criteria of 21 %, and responses were observed in both
squamous and non-squamous histologic subtypes
(Table 3). Rapid (within 9 weeks) and long duration of
responses were reported.
A phase I trial is currently recruiting patients with stage
IIIB/IV NSCLC to evaluate combination therapy of MK-
3475 with cisplatin/pemetrexed or carboplatin/paclitaxel
(NCT01840579). Another phase I trial is assessing the
safety and activity of MK-3475 monotherapy after plati-
num failure in patients with PD-L1-positive advanced
NSCLC (NCT02007070). A phase II/III trial, also currently
recruiting, will compare two doses of MK-3475 versus
docetaxel in participants with PDL-1-positive NSCLC who
have experienced disease progression after platinum-con-
taining systemic therapy (NCT01905657) (Table 2).
Nivolumab
Nivolumab is a fully human anti-PD-1 monoclonal antibody
that binds to the PD-1 receptor, preventing it from engaging
with its ligands. A phase I dose-escalating (0.1–10.0 mg/kg
every 2 weeks) study of nivolumab initially reported results
for 296 patients with advanced solid tumors, including 122
patients with NSCLC [11]. Most NSCLC patients had been
previously treated; 94 % had received platinum-based che-
motherapy and 34 % had received tyrosine kinase inhibitors.
Objective (partial or complete) responses by RECIST v1.0
were reported in 14 of 76 evaluable NSCLC patients (18 %).
The highest ORR (32 %) occurred with 3.0 mg/kg dosing.
Six of 18 patients (33 %) with squamous NSCLC and 7 of 56
Table 1 Clinical results of ipilimumab in combination with chemo-
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patients (12 %) with non-squamous NSCLC had a response.
A longer-term interim analysis of 129 NSCLC patients
enrolled in the study showed longer duration of responses
and more sustained OS with nivolumab compared with
previous reports of data from chemotherapy trials (Table 4).
OS across all NSCLC patients was 42 % at 1 year and 24 %
at 2 years [13]. Based on these findings, further investigation
is being conducted with nivolumab (3.0 mg/kg) in patients
with squamous NSCLC (NCT01642004) (Table 2).
An ongoing phase I trial is evaluating nivolumab as a
monotherapy or in various treatment combinations in
patients with stage IIIB/IV NSCLC (NCT01454102). In the
nivolumab plus chemotherapy arms, patients are random-
ized to receive nivolumab plus gemcitabine/cisplatin, plus
either pemetrexed/cisplatin or carboplatin/paclitaxel, with
safety as the primary assessment. Nivolumab is adminis-
tered every 3 weeks until progression, and chemotherapy is
given for four cycles at standard dosing. Interim results
showed evidence of activity in patients with squamous
NSCLC who received combination therapy; however, no
firm conclusions can be drawn from this small phase I
study [51]. This trial is also evaluating nivolumab in
combination with a targeted agent (erlotinib or bev-
acizumab), nivolumab plus ipilimumab, nivolumab as
switch maintenance monotherapy after platinum doublet,
and nivolumab monotherapy in patients with asymptomatic
brain metastases.
BMS-936559
The fully human anti-PD-L1 antibody BMS-936559 was
studied in a phase I trial of patients with advanced cancer,
including 75 NSCLC patients [7]. The NSCLC patients
experienced responses when treated with the 3.0 mg/kg or
the 10.0 mg/kg dose. Overall, 5 of 49 patients with NSCLC
had an objective response and these responses lasted for
C24 weeks in 3 of these 5 patients. One of 13 patients with
squamous histology and 4 of 36 patients with non-squa-
mous histology had a response; reported ORRs were 8 and
11 %, respectively. Six additional patients, three with
squamous and three with non-squamous histology, had
stable disease lasting at least 24 weeks. At 6 months, the
rates of PFS were 43 and 26 % for patients with squamous
and non-squamous NSCLC, respectively.
MPDL3280A
MPDL3280A is a human anti-PD-L1 monoclonal antibody
containing an engineered immunoglobulin G Fc-domain
designed to optimize efficacy and safety. A phase I dose-
ranging study of MPDL3280A monotherapy in patients
with locally advanced or metastatic NSCLC reported an
initial ORR of 23 % (12 of 53 patients); three patients with
squamous NSCLC and nine patients with non-squamous
NSCLC had a response [15]. Additional patients who were
Fig. 1 Clinical efficacy of phased ipilimumab ? carboplatin/paclit-
axel by histologic subtype in patients with NSCLC [49]. irPFS,
progression-free survival (PFS) by modified WHO (mWHO) criteria
and overall survival (OS) in the phase II randomized study of
ipilimumab administered either in a phased schedule or currently with
paclitaxel/carboplatin in patients with NSCLC, analyzed by histologic
subtype. Comparison of the phased ipilimumab arm versus placebo
arm. Phased ipilimumab plus paclitaxel/carboplatin appeared to have
a greater effect on patients with squamous histology than those with
non-squamous histology. The hazard ratio (HR) point estimates for
irPFS, mWHO-PFS, and OS were significantly smaller with phased
ipilimumab plus paclitaxel/carboplatin in the squamous population
compared with the non-squamous population; however, small sample
size warrants caution in interpretation. Reproduced with permission
from Zielinski et al. [49]
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not included in the ORR (RECIST v1.1) had delayed
responses after apparent radiographic progression.
An additional phase I study, currently recruiting
patients, will evaluate MPDL3280A in combination with
carboplatin/paclitaxel, with carboplatin/pemetrexed, and
with carboplatin/nab-paclitaxel in patients with advanced
or metastatic NSCLC (NCT01633970). Two additional
phase II studies in patients with advanced or metastatic
NSCLC are ongoing. One trial is evaluating objective
responses in patients with PD-L1-positive NSCLC receiv-
ing single-agent MPDL3280A therapy (NCT01846416).
The other trial is evaluating OS and safety of MPDL3280A
compared with docetaxel after platinum therapy failure
(NCT01903993) (Table 2). A phase III trial of similar
design, comparing MPDL3280A with docetaxel, is planned
to start in early 2014 (NCT02008227).
Ongoing trials of immunotherapy in squamous cell
NSCLC
Table 2 lists ongoing phase II and III trials of immune
checkpoint inhibitors in NSCLC, including three trials
specifically in squamous cell carcinoma of the lung.
An ongoing double-blind placebo controlled phase III
study (NCT01285609) is comparing carboplatin (area
under the curve of six) and paclitaxel (175 mg/m2) every
3 weeks with ipilimumab or placebo. The primary end-
point is OS. Patients will receive ipilimumab or placebo
in combination with chemotherapy in a phased schedule,
similar to that used in the phase II study described
above: ipilimumab 10 mg/kg once every 3 weeks for
four doses and then every 12 weeks beginning at week
24.
Table 2 Ongoing phase II and III clinical trials of immune checkpoint inhibitors in NSCLC [50]
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Trials enrolling patients with multiple tumor types, including NSCLC, are not listed
BORR best overall response rate, DOR duration of response, IRC independent radiology review committee, NSCLC non-small cell lung cancer,
ORR objective response rate, OS overall survival, PD-L1 programmed cell death protein-1 ligand-1, PFS progression-free survival, PK phar-
macokinetics, QOL quality of life, TTR time to response
a Enrolled patients have B3 prior therapies
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NCT01721759 is a single arm, multicenter, phase II study
of nivolumab monotherapy in patients with advanced or
metastatic squamous NSCLC who have received at least two
prior treatment regimens. The trial has completed its
enrollment. The primary endpoint is ORR, as determined by
an independent radiology review committee. An ongoing,
randomized open-label phase III study is comparing ORR
and OS with nivolumab monotherapy versus docetaxel in
patients with squamous cell NSCLC who progressed on or
after platinum-based chemotherapy (NCT01642004).
With the exception of one trial enrolling patients with
non-squamous NSCLC (NCT01673867), the additional
ongoing trials listed in Table 2 are enrolling NSCLC
patients who are not segregated at enrollment by histologic
type. However, reports of these clinical trials may present
results based on squamous or non-squamous histology, as
this is frequently a stratification factor.
Potential role of biomarkers in lung cancer
immunotherapy
Predictive biomarkers for checkpoint inhibitor therapy
would help to select patients who are most likely to
respond to this treatment. However, a definitive predictive
biomarker for any of these agents has not been identified.
Expression of the PD-L1 ligand on tumor cells is the most
promising predictive biomarker candidate reported to date
for PD-1 pathway-targeting agents, but data are very lim-
ited at present.
Table 3 Interim phase I efficacy results of MK-3475 monotherapy (10 mg/kg) in evaluable patients with NSCLC [14]





































CI confidence interval, CR complete response, NSCLC non-small cell lung cancer, NR not reached, ORR objective response rate, OS overall
survival, PFS progression-free survival, PR partial response, RECIST response evaluation criteria in solid tumors
a ORR = [(CR ? PR)/n] 9 100; response rate per RECIST v1.1 was based on those patients who had C1 measurable lesion at baseline per
central review. All responses were confirmed except for two
Table 4 Interim phase I efficacy results of nivolumab monotherapy in evaluable patients with NSCLC [13]
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ORR,a n/N (%) [95 % CI] Estimated median response duration,
weeks (range)






























































































CI confidence interval, CR complete response, NSCLC non-small cell lung cancer, NE not estimable, NR not reached, ORR objective response
rate, PR partial response, RECIST response evaluation criteria in solid tumors
a ORR = ([CR ? PR]/n) 9 100; RECIST v1.0
b OS estimates after 1 year reflect censoring and shorter follow-up for patients enrolling later in the study
c One patient had unknown histologic type
d 3.0 mg/kg dosing is being further evaluated in phase III trials
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In an immunohistochemical analysis of pretreatment
biopsy specimens from several tumor types, tumor cell-
surface expression of PD-L1 was significantly correlated
with an objective clinical response to nivolumab mono-
therapy in a dose-ranging phase I study [11]. Nine of 25
patients (36 %) with PD-L1-positive tumors had an objec-
tive response versus 0 of 17 patients with PD-L1-negative
tumors. However, this was a posthoc analysis on a subset of
patients and the investigators urged caution in interpreting
the results. Data correlating anti-PD-1/PD-L1 agent activity
with PD-L1 tumor status are starting to emerge. Although
some associations between PD-L1-positive status and
increased activity have been noted, findings of several
studies, including some in lung cancer, have reported
responses in patients with tumors considered negative for
PD-L1 expression [11, 12, 14, 15, 52]. Additional research is
needed to determine the role of PD-L1 as a potential pre-
dictive marker of response to anti-PD-1 antibody therapy.
Discussion
Histology is now an important consideration for treatment
selection in NSCLC. Currently, patients with squamous
NSCLC have more limited treatment options compared with
patients with NSCLC of non-squamous histology. Immu-
notherapy with checkpoint inhibitors has the promise of
being effective in various subtypes of NSCLC, as it directly
targets tumoral escape mechanisms. Preliminary evidence
suggests that activity with these agents may not be restricted
by specific tumor cell characteristics or histology, and these
results indicate that this novel approach to treatment may
increase treatment options available to patients with squa-
mous NSCLC. The results of ongoing phase II and III clinical
trials of these agents will more clearly determine the future
role for immunotherapy in the management of lung cancer,
particularly for squamous cell carcinoma of the lung.
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